On May 9, 2017 Portola Pharmaceuticals Inc. (Nasdaq:PTLA) reported that clinical results from the Phase 2 study of cerdulatinib in patients with relapsed/refractory b-cell malignancies will be shared in an oral presentation at the International Conference on Malignant Lymphoma (ICML), which is taking place from June 14-17 in Lugano, Switzerland (Press release, Portola Pharmaceuticals, MAY 9, 2017, View Source [SID1234518957]). Schedule your 30 min Free 1stOncology Demo! Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulatinib inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details regarding the oral presentation follow.
Oral Presentation Details:
Abstract Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B-Cell Malignancies
Presenting Author: P.A. Hamlin, Memorial Sloan Kettering Cancer Center
Presentation Date and Time: June 15, 2017 at 4:40 p.m. CEST
Location: Room A, Cinema Corso and Aula Magna (Lugano University)